" /> Protein-engineered Interleukin-2 XTX202 - CISMeF





Preferred Label : Protein-engineered Interleukin-2 XTX202;

NCIt synonyms : Tumor-selective IL-2 XTX202; Engineered IL-2 Prodrug XTX202; Modified IL-2 XTX202; Protein-engineered IL-2 XTX202;

NCIt definition : A modified form of the recombinant form of human endogenous cytokine interleukin-2 (IL-2), that is masked with a protein domain, with potential immunoregulatory and antineoplastic activities. Upon administration of protein-engineered IL-2 XTX202, IL-2 is bound to the protein and pharmacologically inactive. IL-2 does not become active until cleaved by specific proteases in the tumor microenvironment (TME). Upon proteolytic cleavage, unbound and active IL-2 locally binds to the IL-2 receptor beta (CD122) and gamma (CD132) subunits (IL2Rb/g) that are expressed on CD8 T effector cells and natural killer (NK) cells, thereby activating IL2R-mediated signaling within these immune cells. The activation of T- and NK cells mediate cytolytic immune responses against tumor cells causing tumor cell destruction and inhibition of tumor cell proliferation. XTX202 does not bind to IL-2 receptor alpha (IL-2Ra) and does not cause IL-2Ra-mediated toxicities. The selective activation in the TME enhances the IL-2-mediated cytolytic responses against tumor cells while sparing the unwanted effects of systemic, peripheral immune activation.;

Molecule name : XTX-202; XTX 202;

NCI Metathesaurus CUI : CL1778600;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
12/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.